ArcticZymes Technologies — AGM Information 2017

May 11, 2017

Biotec Pharmacon ASA presentation at Annual General Meeting

Biotec Pharmacon ASA presentation at Annual General Meeting

Biotec Pharmacon (OSE:Biotec) presents status for the Group at the Annual

General Meeting today 11 May 2017. Attached is the presentation held by Svein

Lien

For further information

Børge Sørvoll

CFO

+47 952 90187

borge.sorvoll@biotec.no

About Biotec Pharmacon ASA:

Biotec Pharmacon ASA is the parent company of Biotec BetaGlucans AS and

ArcticZymes AS. Biotec BetaGlucans develops, manufactures and markets novel

immunomodulating products, including Woulgan®, a premium priced product in the

advanced wound care market. ArcticZymes develops, produces and markets enzymes

of marine origin used in molecular DNA technologies and diagnostics,

representing growth markets where rapid technological developments are creating

a strong demand for new and improved enzymes.